Antibody titer responses to a single dose of mRNA vaccine were higher in health care workers (HCWs) with previous SARS-CoV-2 infections than those without, according to a research letter published in JAMA Network. In the face of global vaccine shortages, investigators believe this finding could inform single-dose vaccine strategies for previously infected individuals or support lowering their place on the priority list.
A total of 3816 HCWs were enrolled in a sero-survey study conducted in August 2020. Of those, 151 HCWs were randomly contacted, and 59 volunteers enrolled. In the volunteer group, 17 were previously identified as SARS-CoV-2 IgG antibody negative (Ab-negative), 16 IgG-positive with asymptomatic COVID-19 (asymptomatic), and 26 IgG-positive with symptomatic COVID-19 (symptomatic). Participants were vaccinated with either the Pfizer-BioNTech or Moderna vaccine and had their blood drawn at 0, 7, and 14 days.
At each sampling day, the median reciprocal half-maximal binding titers were higher in the asymptomatic (208, 29,364, and 34,033) and symptomatic (302, 32,301, and 35,460) groups vs the Ab-negative group (<50, <50, and 924) (P < .001 for each). Median reciprocal ID99 virus neutralization titers at day 0 and 14 were 80 and 40,960 for the asymptomatic group and 320 and 40,960 for the symptomatic group, both of which again were higher than the Ab-negative group (<20 and 80) (P < .001 for each).
The study was limited by a small sample size and potential bias because the sample may not be representative of the original population. Furthermore, vaccine efficacy data was insufficient.
Investigators did conclude that HCWs with previous COVID-19 (as diagnosed via laboratory-confirmed serology testing) had higher antibody titer responses, which could inform prioritizations of vaccines and potential single-dose vaccination strategy.
Saadat S, Tehrani ZR, Logue J, et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. Published online March 1, 2021. doi:10.1001/jama.2021.334
The post Antibody Response to 1 Dose SARS-CoV-2 mRNA Vaccine in Previously Infected HCWs appeared first on Infectious Disease Advisor.
more recommended stories
Ardena’s Expertise Helps New Treatment for Parkinson’s Disease
Ghent, Belgium 30 August 2021: Ardena,.
The Fight for Air Climb and Other Extraordinary Feats by People With PF
A couple of weeks ago, Bert.
Inflatable Neurostimulator for Minimally Invasive Pain Control
Researchers at the University of Cambridge.
Glucagon-like Peptide-1 Metabolism is Impacted by Anthocyanins and (-)-epicatechin
Obesity and diabetes are major health.
The Last Mile: Overcoming COVID-19 Vaccine Hesitancy
Special thanks to Marc Benjamin, a.
The latest science on staying healthy during pregnancy
New research examines prenatal supplements, how.
Relapsed, Refractory Follicular Lymphoma: CAR-T Cell Therapy Shows Promise
Axicabtagene ciloleucel (axi-cel) appears to be.
Living With PTSD? How to Manage Anxiety and Flashbacks
If you have post-traumatic stress disorder (PTSD), you.
Strategic Partnership Announced Between IDBS and Scitara
Biopharmaceutical lifecycle management platform IDBS (Guildford,.
DLBCL: Naratuximab Shows Promise Among Patients With Relapsed/Refractory Disease
Among patients with diffuse large B.